ENEvgeniya V. Nazarova

Evgeniya V. Nazarova

*This is an algorithmically generated author record based on publicly available information.

Evgeniya V. Nazarova has a total of 104 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    First Russian recombinant allergy vaccine: a brief review of research results

    by Elisyutina Elisyutina, Елисютина Ольга Гурьевна, Natalya I. Ilina, Ильина Наталья Ивановна, Elena S. Fedenko, Феденко Елена Сергеевна, Evgeniia V. Nazarova, Назарова Евгения Валерьевна, Oksana M. Kurbacheva, Курбачева Оксана Михайловна, et al.

    Allergen-specific immunotherapy is a form of etiological treatment for patients with immunoglobulin E mediated allergic diseases. Allergen-specific immunotherapy is based on the administration of causative allergens in order to induce immunological tolerance to it. The main advantages of allergen-specific immunotherapy over all other available treatments for allergy are that it induces long-lasting protection and prevents the progression of the disease to more severe manifestations. This article reviews the results of studies on a promising allergy vaccine developed for allergen-specific immunotherapy in birch pollen allergy.

  • Open Access

    Rare diseases as a global priority: the CIS Orphan Forum and the path toward collaboration with BRICS

    by Nuriya Z. Musina, Ahmed Al Saidi, Ayman W. El-Hattab, Helen Malherbe, Prasanna Kumar B. Shirol, Ulrike Schwerdtfeger, Dilorom I. Akhmedova, Tamara U. Aripova, Bakhyt M. M. Baigaliyeva, Zaure D. Dushimova, et al.

    The Second Orphan Forum of the Commonwealth of Independent States, held in Moscow on June 26–27, 2025, served as a platform to translate World Health Assembly Resolution 78.11 on rare diseases into coordinated policy action. The Forum convened delegates from eight Commonwealth of Independent States members and representatives from India, the United Arab Emirates, South Africa, and Oman, advancing interregional cooperation. Participants highlighted shared challenges: lack of national strategies and harmonized definitions of rare diseases, gaps in diagnostics and care infrastructure, limited registries, shortages of trained specialists, and unstable funding. The adopted Resolution set four priority domains for joint work: policy and regulatory development; organization of care and workforce capacity; pharmaceutical provision and health technology assessment; and international collaboration. Country presentations showed progress alongside persistent gaps. Priorities include expanding screening, establishing centers of expertise, improving patient pathways, extending reimbursement, introducing accelerated regulatory procedures, and updating clinical guidelines. Recommendations emphasize integrated care, continuity from pediatric to adult services, stronger health technology assessment for orphan medicines, real-world data collection, and managed entry and risksharing agreements. The Forum also concluded that closer cooperation on rare diseases is needed within BRICS, especially to improve the efficiency of orphan medicine development, manufacturing, and procurement through coordinated approaches, demand aggregation, and joint price negotiations.

  • Open Access

    Ragweed pollen allergens: description and prospects for the development of new highly effective allergy vaccines

    by Anastasiia V. Shatilova, Aizirek A. Asanbaeva, Marina O. Babikhina, Igor P. Shilovskiy, Sergei M. Andreev, Valerii V. Smirnov, Evgeniya V. Nazarova, George B. Pasikhov, Maiia V. Popova, Polina A. Strueva, et al.

    Ragweed pollen allergy is widespread in the South of Russia, the Far East and other regions, where 25 to 40 % of all weeds-allergic patients may be sensitized specifically to ragweed, representing an important public health problem. Drugs of various pharmacological groups used for the treatment of ragweed pollen allergy affect only the symptoms but not the cause of allergy. Existing pathogenetic therapy (allergen-specific immunotherapy with allergy vaccines based on water-salt extracts) requires long courses and can cause significant side effects. The development of more effective allergy vaccines requires the study of the structures of ragweed pollen allergens and the identification of their IgE epitopes. Based on these epitopes, new highly effective allergy vaccines can be developed using recombinant technologies that will lack the disadvantages of water-salt extracts and will possess the ability to enhance the induction of protective IgG. This review is focused on the epidemiology of ragweed pollen allergy, as well as the latest approaches to the analysis of its allergens’ structures and development of allergy vaccines. Presented information is relevant for the development of new promising highly effective allergy vaccines for allergen-specific immunotherapy of ragweed pollen allergy.


  • Open Access

    Characteristics of the allergic disorder and sensibilization spectrum distributions in the Russian Federation taking into account climatic and geographical features of the regions

    by Evgeniia V. Nazarova, Musa R. Khaitov

    BACKGROUND: Environmental factors have a direct impact on the course and spread of allergic disorders. In recent decades, there has been an increase in the number of patients with allergic pathology, which is partly due to global environmental changes on the planet and insufficient consideration of the specific climatic and geographic environmental factors of the region where the patient lives. AIM: To study the characteristics of epidemiology, etiology and clinical course of allergic disorders in different regions of the Russian Federation. MATERIALS AND METHODS: To achieve this goal, a questionnaire survey of the Chief Consultants was conducted in 2019. Questionnaires were sent to all district, regional, republican centers, and cities of federal significance. The received data were analyzed and structured. RESULTS: Responses to the questionnaires were received from 49 regions of the Russian Federation, where a total of 1,468,105 patients with allergic diseases were registered during the study period. Significant discrepancies in the distribution of allergic disorders and the spectrum of etiologically significant allergens were revealed in different regions of the Russian Federation, reflecting their climatic and geographical peculiarities. There is an increase in respiratory forms of allergy, multisensitization and multi-organ allergic lesions. The Ural Federal District has the lowest number of cases of allergic rhinitis (p = 0.001) among the studied regions, and bronchial asthma is more common than other forms of respiratory allergy (p 0.001), while in the Southern Federal District the prevalence of this disease was statistically significantly lower than in the northern regions (p 0.001). Atopic dermatitis was more frequently registered in the Volga and Far Eastern Federal Districts (p = 0.009, p = 0.012), food allergy – in the Volga and Northwestern Federal Districts (p = 0.008, p = 0.003). In the North Caucasian and Siberian Federal Districts, food allergy was diagnosed least frequently (p = 0.001, p = 0.002). The Northwestern Federal District registered the smallest number of patients with sensitization to house dust allergens (p 0.001), and the Southern Federal District – to house dust mites (p = 0.004). The lowest number of patients with sensitization to weed pollen allergens was noted in the Northwestern Federal District (p 0.001). The Southern and North Caucasian Federal Districts dominate in terms of sensitization to weed pollen allergens (p 0.001, p = 0.001) and show a low percentage of sensitization to tree allergens (p 0.001) compared to other federal districts. Low sensitization of patients to mold allergens is noted in the Ural Federal District (p 0.001). The highest proportion of insect allergy is noted in the Siberian (p = 0.001), and the lowest – in the Central Federal District (p 0.001). The North Caucasian Federal District showed the lowest percentage of sensitization to food allergens (p = 0.04). Low availability of specialized care and insufficient prescription of pathogenetic allergen-specific immunotherapy were found in all federal districts of the Russian Federation. CONCLUSION: Different climatic and geographic regions of the Russian Federation differ from each other in the structure of allergic diseases and sensitization spectrum, which should be taken into account in the development of preventive, diagnostic and therapeutic measures in these territories.


  • Telemedicine technologies in allergology: implementation experience in clinical practice, problems and perspectives

    by Evgeniia Nazarova, Назарова Евгения Валерьевна

    In 2020, the need for widespread restriction of social contacts around the world has raised the issue of alternative types of medical care and, in particular, the development of online consultations with physicians of subspecialties. However, even before the Covid-19 pandemic, telemedicine technologies were demonstrating their ability to save financial and time resources, increase access to health services and improve adherence to treatment for patients with allergic diseases. Despite some technical and legal difficulties associated with the organization of remote appointments, the clinic of the National Research Center – Institute of Immunology Federal Medical-Biological Agency managed to successfully implement a platform for telemedicine consultations. During the period from 1.09.2020 to 19.04.2024, 4675 patients were consulted, 945 of whom filled out a questionnaire on the quality of medical care provided. According to the results of analyzing the obtained data, we observed high patient satisfaction with the new medical service as well as economic profitability of the project. The purpose of this article is to provide a visual overview of the world and domestic experience of telemedicine implementation in the clinical practice of an allergist, to tell about the way of organization and operation of the platform for telemedicine consultations in the National Research Center – Institute of Immunology Federal Medical-Biological Agency, and to highlight the current state of the problem.

  • Open Access

    Efficacy and safety of levosalbutamol in patients with mild to moderate asthma compared with racemic salbutamol: results of a crossover placebo-controlled study

    by Oksana M. Kurbacheva, Natalia I. Ilina, Sergey N. Avdeev, Natalia M. Nenasheva, Irina I. Isakova, Evgeniya V. Nazarova, Olga P. Ukhanova, Maria V. Vershinina

    Aim. Effectiveness and safety of levosalbutamol metered dose inhaler (MDI) in comparison with placebo and salbutamol. Materials and methods. In this multicenter, randomized, placebo-controlled, 3-period crossover study, all asthma patients (n=91) received levosalbutamol (90 mcg), salbutamol (180 mcg), and placebo using standard MDI. Pulmonary function testing – forced expiratory volume in the first second (FEV1) and forced vital capacity (FVC) – was performed 45 and 15 minutes before and 5, 10, 15, 30, 60, 90, 120, 180, 240, 300 and 360 minutes after dosing. The primary efficacy endpoint was the baseline-corrected area under FEV1 curve from 0 to 6 hours (AUC(0–6h)). Secondary endpoints were the baseline adjusted FEV1 and FVC peak values, as well as the onset of drug action. Results. The FEV1 AUC0–6 hours analysis confirmed similar bronchodilatory levosalbutamol and salbutamol effect (p=0.595), significantly improved compared with placebo (p0.001). The peak values of FEV1 and FVC after levosalbutamol or salbutamol dosing were similar (p=0.643) and significantly higher compared with placebo group (p0.001). The active therapy effect was observed 5 minutes after dosing and throughout the entire observation period up to 6 hours, however, there was some tendency towards a longer duration of action of levosalbutamol compared to salbutamol. Levosalbutamol was well tolerated by patients; after levosalbutamol dosing twiсе fewer adverse reactions were observed compared to salbutamol. Conclusion. Levosalbutamol at a 90-mcg dose showed efficacy similar to that of salbutamol at a dose of 180 mcg, assosiated with a good safety profile.


  • Tablet-lyophilizate containing a mixture of house dust mites usage for skin prick testing to confirm house dust mites sensitization

    by Evgeniya V. Nazarova, Anastasia S. Primak

    BACKGROUND: Since 2021, the production of water-salt allergens for skin allergy tests with household allergens has been suspended, which has led to the lack of an objective opportunity for skin prick tests in medical and preventive institutions in the Russian Federation. Quantitative determination of allergen-specific immunoglobulin class E in the blood serum by the ImmunoCAP method is currently difficult because of the lack of supplies in the laboratory. AIMS: To assess the possibility of using a drug solution of a lyophilizate mixture of house dust mites (Acarisax) containing house dust allergens Dermatophagoides pteronyssinus and Dermatophagoides farinae in equal amounts 12 SQ-HDM for the skin hood tests to confirm the sensitization of patients with mites of home dusts. MATERIALS AND METHODS: Skin prick tests were conducted with dilutions of one tablet per 2.5 and 5 mL of diluting liquid of the study drug with positive and negative controls. Statistical analysis was conducted using Statistica 13.3 or IBM SPSS 17.0. To analyze efficacy and safety, standard parametric tests were used: Students t-test for dependent/independent samples, analysis of variance for repeated measurements, MannWhitney U-test, and ShapiroWilk test. The analysis of AEs was based on an estimate of the frequency of undesirable phenomena/serious undesirable phenomena. RESULTS: The correlation was estimated between the total level of specific IgE to tick-borne allergens D. pteronyssinus and D. farinae measured during screening and the papule size 20 min after applying the drug in breeding with one tablet per 2.5 mL and 5 mL of a diluting liquid. The correlation coefficients (R) in both groups (total) were 0.735 (high correlation) and 0.762 (high correlation). The result was statistically significant (p 0.05) in both groups. The clinical test showed that the lyophilizate drug, a mixture of domestic dust mites containing dermal dust allergens D. pteronyssinus and D. farinae in equal quantities 12 SQ-HDM is a safe and informative method when used in skin hood tests to confirm the sensitization of patients to domestic dust ticks. CONCLUSIONS: For skin hood tests, to confirm the sensitization of patients to domestic dust ticks, the studied drug can be used in greater dilution one tablet per 5 mL of the diluting fluid. The lyophilizate mixture of dust mites containing D. pteronyssinus and D. farinae homemade allergens 12 SQ-HDM is safe and well tolerated by patients when used in skin test tests.


  • Post-vaccination and post-infection humoral immune response to the SARS-CoV-2 infection

    by I.V. Andreev, K.O. Nechay, A.I. Andreev, A.P. Zubaryova, G.N. Gabrichevsky Moscow Scientifi c Research Institute of Epidemiology and Microbiology Federal Service for Surveillance of Consumer Rights Protection and Human Wellbeing, D.R. Esaulova, A.M. Alenova, I.а. Nikolaeva, O.P. Chernyavskaya, K.S. Lomonosov, et al.

    Поствакцинальный и постинфекционный гуморальный иммунный ответ на инфекцию SARS-CoV-2


  • Pharmacoeconomic analysis of bronchial asthma prophylaxis in adults and children with allergic rhinitis by means of sublingual allergen-specific immunotherapy

    by Valeriya A. Lemeshko, Svetlana S. Ratushnyak, Filipp V. Gorkavenko, Evgeniya V. Nazarova, Natalia I. Ilina, Vitaly V. Omelyanovskiy, Омельяновский Виталий Владимирович

    BACKGROUND: Allergic rhinitis is the most common chronic allergic disease worldwide, and bronchial asthma (BA) is one of the most severe complications of allergic rhinitis. Clinical studies reported that sublingual allergen-specific immunotherapy can reduce the incidence of bronchial asthma in children and adults. However, allergen-specific immunotherapy is rather expensive and is not reimbursed by the state, which transfers the cost of this therapy to patients. AIMS: To evaluate the cost-effectiveness of allergen-specific immunotherapy in children and adults with allergic rhinitis and/or allergic rhinoconjunctivitis MATERIALS AND METHODS: The study hypothesized based on study results by Devillier P. et al. in 2019, to which the incidence of asthma was 13.7% and 17.0% in the sublingual allergen-specific immunotherapy + symptomatic therapy and the symptomatic therapy group, respectively (odds ratio: 0.776, 95% confidence interval [0.622; 0.968]). Pharmacoeconomic study based on decision tree model. Costs taken into account are the following: allergen-specific immunotherapy, symptomatic therapy, diagnostics, and routine follow-up visits due to bronchial asthma, outpatient bronchial asthma drug therapy, and hospitalization due to bronchial asthma. The modeling horizon was 5 years, including 2 years of allergen-specific immunotherapy therapy and 3 years of follow-up. RESULTS: The cost per patient when using allergen-specific immunotherapy in combination with symptomatic therapy was 166,711.93 rubles, whereas with symptomatic therapy was 101,700.35 rubles. The cost-effectiveness ratio for allergen-specific immunotherapy in combination with symptomatic therapy was 193,177.20 rubles per 1 prevented case of asthma, whereas 122,530.55 rubles for symptomatic therapy for 1 prevented case of bronchial asthma. Thus, the cost of 1 averted bronchial asthma case when using allergen-specific immunotherapy in combination with symptomatic therapy is 57.7% higher than with symptomatic therapy. The cost-benefit analysis result revealed that the incremental cost-utility ratio for an additional year of life adjusted for its quality when performing sublingual allergen-specific immunotherapy in combination with symptomatic therapy compared with symptomatic therapy alone in children and adults was 567,365.48 rubles, which is less than the calculated willingness to pay threshold (RUB 2,248,898.50). CONCLUSIONS: The comparison results of the cost of 1 added quality adjusted life years and willingness to pay threshold concluded that sublingual allergen-specific immunotherapy in combination with symptomatic therapy compared to symptomatic therapy alone is potentially cost-effective in children and adults with allergic rhinitis.


  • Vaccination against COVID-19 for patients with primary immunodeficiency and hereditary angioedema: the position paper of the Russian Association of Allergology, Clinical Immunology, and the National Association of Experts in Primary Immunodeficiencies

    by Natalya I. Ilyina, Irina Vadimovna Kondratenko, Elena A. Latysheva, Tatiana V. Latysheva, Irina A. Manto, Evgeniya V. Nazarova, Dar'Ya S. Fomina, Musa R. Khaitov, Anna Yu. Shcherbina, Ильина Наталья Ивановна, et al.

    Since the end of 2019, the whole world has been suffering from the Corona virus-19 (COVID-19) pandemic due to the potentially severe acute respiratory infection caused by the SARS-CoV-2 virus. To date, the infection has led to more than 4 million deaths worldwide, and 140 thousand deaths in Russia. Vaccination against COVID-19 plays a key role in stopping the pandemic. According to the existing experience in infection prevention, mass vaccination will reduce the viruss expansion and the risk of vaccine-resistant strains developing. In the context of COVID-19, the question of the feasibility and safety of vaccination for patients with primary immunodeficiency and hereditary angioedema arises. The Russian Association of Allergists, Clinical Immunologists, and the National Association of Experts in Primary Immunodeficiencies have developed and approved a position paper on the vaccination for patients with primary immunodeficiency and hereditary angioedema against COVID-19. This position paper provides answers to key questions regarding vaccination for patients with these diseases.